RARE

Ultragenyx Pharm

• Reuters·04/02 15:48

  BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford

• Reuters·04/02 14:31

  BUZZ-Ultragenyx rises after FDA accepts marketing application for rare disease therapy

• Reuters·04/02 12:35

  FDA accepts Ultragenyx resubmitted UX111 BLA for Sanfilippo syndrome A therapy

• Benzinga·04/02 12:35

  Ultragenyx Says FDA Accepts Resubmitted BLA For Review Seeking Accelerated Approval For UX111 AAV9 Gene Therapy As Treatment For Patients With Sanfilippo Syndrome Type A; FDA Sets PDUFA Action Date Of Sept. 19

• Reuters·04/02 12:32

  Ultragenyx says FDA accepts UX111 gene therapy BLA resubmission, sets Sept. 19 PDUFA date

• Reuters·04/02 12:30

  ULTRAGENYX PHARMACEUTICAL INC - UX111 TO BE MANUFACTURED IN U.S. AT ANDELYN BIOSCIENCES AND ULTRAGENYX FACILITY IF APPROVED

• Reuters·03/30 15:53

  BUZZ-U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar

• Reuters·03/30 13:12

  BUZZ-U.S. STOCKS ON THE MOVE-Insmed, United Therapeutics, CrowdStrike

• Reuters·03/30 12:46

  BUZZ-Ultragenyx rises after FDA clears human trial for rare muscle disease drug

• Reuters·03/30 12:32

  Ultragenyx wins FDA IND clearance for UX016 in GNE myopathy

• Benzinga·03/30 12:31

  Ultragenyx Pharmaceutical Receives FDA Clearance For Its Investigational New Drug Application For UX016 To Treat GNE Myopathy

• Reuters·03/30 12:30

  ULTRAGENYX PHARMACEUTICAL INC - PHASE 1/2 STUDY OF UX016 EXPECTED TO BEGIN IN H2 2026

• Reuters·03/27 20:32

  Ultragenyx announces annual stockholders meeting; FY2025 revenue grows 20%

• Dow Jones·03/24 17:36

  Ultragenyx Pharma Price Target Cut to $25.00/Share From $61.00 by Goldman Sachs